Histone deacetylase inhibitors in the generation of the anti-tumour immune response

Leggatt, Graham R. and Gabrielli, Brian (2012) Histone deacetylase inhibitors in the generation of the anti-tumour immune response. Immunology and Cell Biology, 90 1: 33-38. doi:10.1038/icb.2011.94

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ267536.pdf Full text (Open Access) application/pdf 285.54KB 0

Author Leggatt, Graham R.
Gabrielli, Brian
Title Histone deacetylase inhibitors in the generation of the anti-tumour immune response
Journal name Immunology and Cell Biology   Check publisher's open access policy
ISSN 0818-9641
1440-1711
Publication date 2012-01-01
Year available 2011
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1038/icb.2011.94
Volume 90
Issue 1
Start page 33
End page 38
Total pages 6
Place of publication London, United Kingdom
Publisher Nature Publishing Group
Collection year 2012
Language eng
Abstract Acetylation of lysine residues acts to modify the function of a wide range of proteins. In histones, it affects chromatin structure, which can impact gene transcription, whereas acetylation of transcription factors and heat-shock proteins affect their activity. Deacetylase inhibitors block the dynamic turnover of acetylation resulting in hyperacetylation of target proteins. This can affect a wide range of cellular functions, and in a wide range of tumour cell types promote cytostatic and cytotoxic effects, but has little effect on normal cells. The inhibitors are being used clinically as anti-cancer agents. Although direct effects of the histone deacetylase (HDAC) inhibitors on cancers are beginning to be elucidated, the prospect of concurrent stimulation of the immune response raises hopes for immune attack of the tumour as part of the initial anti-cancer therapy and long-term immunesurveillance of residual or recurrent tumour. This review will examine the evidence for the generation of anti-tumour immunity after treatment of cancers with HDAC inhibitors.
Keyword HDAC inhibitor
Tumour
Immunotherapy
Chemotherapy
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online: 8 November 2011.

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Non HERDC
ERA White List Items
UQ Diamantina Institute - Open Access Collection
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 16 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 12 Feb 2012, 10:17:15 EST by System User on behalf of UQ Diamantina Institute